指南与共识间质性肺疾病

类风湿关节炎相关间质性肺病:筛查、诊断与治疗专家共识

Rheumatoid arthritis-associated interstitial lung disease: screening, diagnosis, and treatment-an expert group consensus statement.
指南 / 共识 · Lancet Respir Med · 2026-06-05

间质性肺病是类风湿关节炎常见且致病的并发症,但筛查时机、治疗启动和方案尚无共识。因缺乏高质量研究,多学科专家组对现有证据定性综合,形成关于风险因素、筛查和治疗的意见书,以指导临床及时诊断、监测进展并适时治疗。

要点

  • 类风湿关节炎患者需关注间质性肺病风险因素并开展筛查。
  • 对已确诊类风湿关节炎相关间质性肺病应持续监测疾病进展。
  • 治疗启动时机与方案需参考专家共识意见。

核心结论

  • 专家组就类风湿关节炎相关间质性肺病的风险因素、筛查和治疗形成共识意见,以辅助临床决策。

研究设计与样本

  • 多学科类风湿关节炎相关间质性肺病专家组对现有证据进行定性综合并形成共识声明。

临床怎么用

  • 指导临床医生对类风湿关节炎患者中间质性肺病风险者进行筛查和监测。
  • 对已确诊类风湿关节炎相关间质性肺病患者适时启动治疗。

局限性

  • 缺乏高质量研究,无法制定严格的循证指南。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Interstitial lung disease (ILD) is a common and morbid complication of rheumatoid arthritis. Despite its prevalence and impact on patients, there is no agreement on how to screen for rheumatoid arthritis-associated ILD, when to initiate treatment, and the optimal treatment regimen. Due to a scarcity of high-quality studies to guide strict evidence-based guidelines, a multidisciplinary group of rheumatoid arthritis-associated ILD experts was convened to discuss the current body of evidence, synthesise the evidence qualitatively, and provide clinically useful consensus statements pertaining to the risk factors for rheumatoid arthritis-associated ILD, screening for ILD in rheumatoid arthritis, and the treatment of rheumatoid arthritis-associated ILD. These statements are meant to guide clinicians caring for patients with rheumatoid arthritis at risk for ILD and those with established rheumatoid arthritis-associated ILD to facilitate a timely diagnosis, ongoing monitoring of disease progression, and initiation of treatment when appropriate.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

引用

  1. Solomon JJ, Dieudé P, Matson SM, et al. Rheumatoid arthritis-associated interstitial lung disease: screening, diagnosis, and treatment-an expert group consensus statement. Lancet Respir Med. 2026. PMID: 42248165. doi:10.1016/S2213-2600(26)00094-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。